These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Differential Transmission of Antiviral Drug-Resistant Chikungunya Viruses by Delang L; Yen PS; Vallet T; Vazeille M; Vignuzzi M; Failloux AB mSphere; 2018 Aug; 3(4):. PubMed ID: 30135220 [TBL] [Abstract][Full Text] [Related]
47. Preparation of vesicular stomatitis virus pseudotype with Chikungunya virus envelope protein. Tong W; Yin XX; Lee BJ; Li YG Acta Virol; 2015 Jun; 59(2):189-93. PubMed ID: 26104337 [TBL] [Abstract][Full Text] [Related]
48. Chikungunya virus induces a more moderate cytopathic effect in mosquito cells than in mammalian cells. Li YG; Siripanyaphinyo U; Tumkosit U; Noranate N; A-nuegoonpipat A; Tao R; Kurosu T; Ikuta K; Takeda N; Anantapreecha S Intervirology; 2013; 56(1):6-12. PubMed ID: 22907160 [TBL] [Abstract][Full Text] [Related]
49. A polarized cell model for Chikungunya virus infection: entry and egress of virus occurs at the apical domain of polarized cells. Lim PJ; Chu JJ PLoS Negl Trop Dis; 2014 Feb; 8(2):e2661. PubMed ID: 24587455 [TBL] [Abstract][Full Text] [Related]
50. Host Factors and Pathways Involved in the Entry of Mosquito-Borne Alphaviruses. De Caluwé L; Ariën KK; Bartholomeeusen K Trends Microbiol; 2021 Jul; 29(7):634-647. PubMed ID: 33208275 [TBL] [Abstract][Full Text] [Related]
51. Suramin Inhibits Chikungunya Virus Entry and Transmission. Ho YJ; Wang YM; Lu JW; Wu TY; Lin LI; Kuo SC; Lin CC PLoS One; 2015; 10(7):e0133511. PubMed ID: 26208101 [TBL] [Abstract][Full Text] [Related]
52. Structural basis of Chikungunya virus inhibition by monoclonal antibodies. Zhou QF; Fox JM; Earnest JT; Ng TS; Kim AS; Fibriansah G; Kostyuchenko VA; Shi J; Shu B; Diamond MS; Lok SM Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27637-27645. PubMed ID: 33087569 [TBL] [Abstract][Full Text] [Related]
54. The CD147 Protein Complex Is Involved in Entry of Chikungunya Virus and Related Alphaviruses in Human Cells. De Caluwé L; Coppens S; Vereecken K; Daled S; Dhaenens M; Van Ostade X; Deforce D; Ariën KK; Bartholomeeusen K Front Microbiol; 2021; 12():615165. PubMed ID: 33717005 [TBL] [Abstract][Full Text] [Related]
55. CHIKV strains Brazil (wt) and Ross (lab-adapted) differ with regard to cell host range and antiviral sensitivity and show CPE in human glioblastoma cell lines U138 and U251. Hucke FIL; Bestehorn-Willmann M; Bassetto M; Brancale A; Zanetta P; Bugert JJ Virus Genes; 2022 Jun; 58(3):188-202. PubMed ID: 35347588 [TBL] [Abstract][Full Text] [Related]
56. Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design. Taylor A; Liu X; Zaid A; Goh LY; Hobson-Peters J; Hall RA; Merits A; Mahalingam S mBio; 2017 Feb; 8(1):. PubMed ID: 28223458 [TBL] [Abstract][Full Text] [Related]
57. Genome-Wide Approaches to Unravel the Host Factors Involved in Chikungunya Virus Replication. Tanaka A; Suzuki Y Front Microbiol; 2022; 13():866271. PubMed ID: 35401487 [TBL] [Abstract][Full Text] [Related]
58. Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission. Wang YM; Lu JW; Lin CC; Chin YF; Wu TY; Lin LI; Lai ZZ; Kuo SC; Ho YJ Antiviral Res; 2016 Nov; 135():81-90. PubMed ID: 27742486 [TBL] [Abstract][Full Text] [Related]
60. Recent progress on chikungunya virus research. An W; Ge N; Cao Y; Sun J; Jin X Virol Sin; 2017 Dec; 32(6):441-453. PubMed ID: 29188427 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]